THC - Tenet Healthcare down amid Street concern 2023 guidance not provided in fiscal 2022 update

• Tenet Healthcare ( NYSE: THC ) is off 4% in Thursday afternoon trading after some Street analysts expressed concern that it did not provide 2023 guidance in a preliminary fiscal 2022 EBITDA announcement Thursday morning.
• The hospital operator's adjusted EBITDA for fiscal 2022 is expected to slightly exceed $3.425B .
• Citi's Jason Cassorla, who has a buy rating on shares, said that the lack of any 2023 guidance could bring up questions about the company's outlook especially given the company also revealed management changes on Thursday.
• However, he added that he sees continued growth for Tenet ( THC ) despite headwinds in the near term.
• Truist is also maintaining its buy rating, saying that Tenet ( THC ) company has a strong presence in its field and it sees improved balance sheet optionality this year.
• Seeking Alpha's Quant Rating views Tenet ( THC ) as a hold with high marks for valuation and profitability .

For further details see: